Novavax on Wednesday raised its full-year revenue forecast as it received a $175 million milestone payment from Sanofi ...

Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad will return to the agency.

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

At the U.S. Food and Drug Administration's (FDA) request, Vinay Prasad is returning to the role of director of the Center for ...

Less than weeks after stepping down, Prasad will return to lead CBER “at the FDA’s request,” according to an HHS spokesperson ...

The Food and Drug Administration restored a top vaccine regulator to his position at the agency just weeks after firing him.

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

U.S. President Donald Trump's ally and far-right political activist, Laura Loomer, alleged on Sunday that the rehiring of ...

Vinay Prasad is leaving Sensible Medicine to take a senior role at the US FDA. He has our enthusiastic support. Prasad is ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related ...